HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), NPC1L1 inhibitors(Niemann-Pick C1-like protein 1 inhibitors), Cholesterol absorption inhibitors

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Egis Gyógyszergyár Zrt.

Active Organization

Egis Gyógyszergyár Zrt.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

Netherlands (05 Feb 2014)

Regulation-

Structure/Sequence

Molecular FormulaC44H54F2N6O12S2Zn

InChIKeyKUQHZGJLQWUFPU-UHFFFAOYSA-L

CAS Registry953412-08-3

View All Structures (2)

Clinical Trials associated with Ezetimibe/Rosuvastatin Zinc

NCT06186037

/ RecruitingPhase 4IIT

Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients with Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention : a Prospective, Multicenter, Randomized, Open-label Trial

[Purpose of the Clinical Study]:The purpose of this study is to conduct a clinical comparison of low-dose rosuvastatin plus ezetimibe combination therapy and high-dose rosuvastatin monotherapy in patients with minimal to intermediate coronary artery disease without percutaneous coronary intervention to confirm non-inferiority in the reduction of key cardiovascular events.
[Hypothesis]:In patients who have not undergone percutaneous coronary intervention for minimal to moderate coronary artery disease, low-dose rosuvastatin and ezetimibe combination therapy are non-inferior in terms of reducing major cardiovascular events compared to high-dose rosuvastatin monotherapy.

Start Date01 Feb 2024

Sponsor / Collaborator-

NCT05889143

/ Active, not recruitingNot Applicable

A Prospective, Non-Intervention, Multi-Center Observational Study to Evaluate the Efficacy and Safety of CREZET Tablet in Patients With Dyslipidemia

This observation study is to evaluate blood lipid-lowering effects and liver/renal safety, changes in HbA1c and FPG in patients with dyslipidemia who administered CREZET tablets for 24 weeks.

Start Date24 May 2023

Sponsor / Collaborator

Daewoong Pharmaceutical Co., Ltd.

NCT04669041

/ CompletedPhase 3

A Randomized Double-blinded, Double Dummy, Active-controlled, Parallel Design, Phase 3 Clinical Trial to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia, Not Adequately Controlled on Statin Therapy

Primary Objective:
To demonstrate the superiority of the single pill combination (SPC) ezetimibe 10 mg/rosuvastatin 10 mg (E10/R10) compared to rosuvastatin 10 mg (R10), in the reduction of low density lipoprotein cholesterol (LDL-C) after 8 weeks.
Secondary Objectives:
To evaluate the proportion of patients who attain their LDL-C goal.
To evaluate the effect of SPC (E10/R10) compared to rosuvastatin 10 mg (R10) in reduction of LDL-C at Week 4.
To evaluate the effect of SPC (E10/R10) compared to R10 on other lipid parameters at Week 4 and Week 8.
To evaluate the safety of SPC (E10/R10) and R10.

Start Date08 Dec 2020

Sponsor / Collaborator

Sanofi

100 Clinical Results associated with Ezetimibe/Rosuvastatin Zinc

100 Translational Medicine associated with Ezetimibe/Rosuvastatin Zinc

100 Patents (Medical) associated with Ezetimibe/Rosuvastatin Zinc

100 Deals associated with Ezetimibe/Rosuvastatin Zinc

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C10BA	-

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis